G. Steven Burrill

Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC.

Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY.

Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC.

Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC.

ProteoGenix is the first and only company solely committed to developing minimally invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes. By applying innovative proteomic and molecular technologies, ProteoGenix has quickly become a leader in developing powerful diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management. In 2002, four leading researchers in the area of perinatology and neonatology joined together to create ProteoGenix, a company dedicated to solving the mysteries of preterm birth and the significant medical, emotional and economic consequences that prematurity has on their society. Their passion for improving pregnancy management and the outcomes associated with preterm birth, along with their clinical expertise and scientific acumen, led ProteoGenix to achieve a truly significant recent scientific discovery identification of The Proteomic Map of Pregnancy. The physicians and scientists that became ProteoGenix were the first to identify and characterize a fundamental map of the key biologic fluids in pregnancy and show how this landscape changes in important pregnancy-related disorders. This groundbreaking work has received several significant scientific awards, including Best Clinical Study at the 2007 annual meeting of the Society for Maternal-Fetal Medicine, and has been the topic of numerous peer-reviewed publications. ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular microbiology techniques such as quantitative Polymerase Chain Reaction (PCR) and Pyrosequencing, specifically optimized for use in key maternal, fetal, neonatal biological fluids to detect infectious and path physiological diseases associated with pregnancy.

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC.

Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ.

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California.

Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY.

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC.

Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC.

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY.

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY.

Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY.

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

BioImagene, Inc. provides innovative digital pathology solutions for the anatomic pathology laboratory. They are in the business of cancer diagnosis and its goal is to make detection, diagnosis, and therapy selection more accurate, efficient, reliable, and accessible. The firm's solutions allow pathologists to collaborate, learn, educate and provide more reliable and consistent diagnoses. Further, its solutions improve the efficiency of laboratory workflow. BioImagene provides digital pathology solutions. Its systems automate pathology workflows for acquisition, analysis, management, archival, reporting, and sharing of tissue images. The firm offers solutions for pathologists, researchers, and drug developers.

Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California.

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ.

Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ.

Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC.

BioImagene, Inc. provides innovative digital pathology solutions for the anatomic pathology laboratory. They are in the business of cancer diagnosis and its goal is to make detection, diagnosis, and therapy selection more accurate, efficient, reliable, and accessible. The firm's solutions allow pathologists to collaborate, learn, educate and provide more reliable and consistent diagnoses. Further, its solutions improve the efficiency of laboratory workflow. BioImagene provides digital pathology solutions. Its systems automate pathology workflows for acquisition, analysis, management, archival, reporting, and sharing of tissue images. The firm offers solutions for pathologists, researchers, and drug developers.

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC.

Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY.

Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC.

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY.

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ.

Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC.

Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ.

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

ProteoGenix is the first and only company solely committed to developing minimally invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes. By applying innovative proteomic and molecular technologies, ProteoGenix has quickly become a leader in developing powerful diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management. In 2002, four leading researchers in the area of perinatology and neonatology joined together to create ProteoGenix, a company dedicated to solving the mysteries of preterm birth and the significant medical, emotional and economic consequences that prematurity has on their society. Their passion for improving pregnancy management and the outcomes associated with preterm birth, along with their clinical expertise and scientific acumen, led ProteoGenix to achieve a truly significant recent scientific discovery identification of The Proteomic Map of Pregnancy. The physicians and scientists that became ProteoGenix were the first to identify and characterize a fundamental map of the key biologic fluids in pregnancy and show how this landscape changes in important pregnancy-related disorders. This groundbreaking work has received several significant scientific awards, including Best Clinical Study at the 2007 annual meeting of the Society for Maternal-Fetal Medicine, and has been the topic of numerous peer-reviewed publications. ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular microbiology techniques such as quantitative Polymerase Chain Reaction (PCR) and Pyrosequencing, specifically optimized for use in key maternal, fetal, neonatal biological fluids to detect infectious and path physiological diseases associated with pregnancy.

Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC.

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY.